PSNL

In the past six months, Personalis reported strong Q1 2026 results with significant clinical volume growth and reaffirmed its 2026 guidance. Regulatory milestones in June-July 2026 included obtaining Class A CE-IVD marking for specimen collection kits and UKCA marking for the NeXT Personal Dx test, facilitating global expansion. On July 20, 2026, Tempus AI announced an agreement to acquire Personalis for $16.25 per share, causing a -13.32% stock price change, with the merger waiting period ending October 6, 2026. Q2 2026 results showed a 30% year-over-year increase in total revenue and a 442% increase in clinical revenue. As of October 8, 2026, the stock closed at $16.06, reflecting an 85.0% gain over 12 months, near its 52-week high, with analysts holding a 'Hold' rating and an average price target of $15.17.